MEI Pharma, Inc. (MEIP)
Total Valuation
MEI Pharma has a market cap or net worth of $26.65 million. The enterprise value is -$20.80 million.
Market Cap | 26.65M |
Enterprise Value | -20.80M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
Earnings Date | May 9, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
MEI Pharma has 6.66 million shares outstanding.
Shares Outstanding | 6.66M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.55% |
Owned by Institutions (%) | 47.60% |
Float | 4.94M |
Valuation Ratios
The trailing PE ratio is 1.35.
PE Ratio | 1.35 |
Forward PE | n/a |
PS Ratio | 0.37 |
Forward PS | 298.62 |
PB Ratio | 0.45 |
P/FCF Ratio | n/a |
PEG Ratio | 20.60 |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.23, with a Debt / Equity ratio of 0.20.
Current Ratio | 8.23 |
Quick Ratio | n/a |
Debt / Equity | 0.20 |
Debt / EBITDA | 0.55 |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 39.70% and return on invested capital (ROIC) is 22.21%.
Return on Equity (ROE) | 39.70% |
Return on Assets (ROA) | 18.30% |
Return on Capital (ROIC) | 22.21% |
Revenue Per Employee | $1.58M |
Profits Per Employee | $431,391 |
Employee Count | 46 |
Asset Turnover | 0.67 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.97% in the last 52 weeks. The beta is 0.65, so MEI Pharma's price volatility has been lower than the market average.
Beta (1Y) | 0.65 |
52-Week Price Change | -11.97% |
50-Day Moving Average | 4.27 |
200-Day Moving Average | 5.99 |
Relative Strength Index (RSI) | 48.91 |
Average Volume (30 Days) | 24,349 |
Short Selling Information
The latest short interest is 9,096, so 0.14% of the outstanding shares have been sold short.
Short Interest | 9,096 |
Short Previous Month | 12,480 |
Short % of Shares Out | 0.14% |
Short % of Float | 0.18% |
Short Ratio (days to cover) | 0.32 |
Income Statement
In the last 12 months, MEI Pharma had revenue of $72.65 million and earned $19.84 million in profits. Earnings per share was $2.97.
Revenue | 72.65M |
Gross Profit | 72.65M |
Operating Income | 15.88M |
Pretax Income | 19.84M |
Net Income | 19.84M |
EBITDA | 21.69M |
EBIT | 19.84M |
Earnings Per Share (EPS) | $2.97 |
Balance Sheet
The company has $59.48 million in cash and $12.03 million in debt, giving a net cash position of $47.45 million or $7.12 per share.
Cash & Cash Equivalents | 59.48M |
Total Debt | 12.03M |
Net Cash | 47.45M |
Net Cash Per Share | $7.12 |
Equity / Book Value | 59.49M |
Book Value Per Share | 8.93 |
Working Capital | 58.13M |
Cash Flow
In the last 12 months, operating cash flow was -$52.98 million and capital expenditures -$55,000, giving a free cash flow of -$53.03 million.
Operating Cash Flow | -52.98M |
Capital Expenditures | -55,000 |
Free Cash Flow | -53.03M |
FCF Per Share | -$7.96 |
Margins
Gross margin is 100.00%, with operating and profit margins of 21.86% and 27.32%.
Gross Margin | 100.00% |
Operating Margin | 21.86% |
Pretax Margin | 27.32% |
Profit Margin | 27.32% |
EBITDA Margin | 29.85% |
EBIT Margin | 27.32% |
FCF Margin | -73.00% |
Dividends & Yields
MEI Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | 74.46% |
FCF Yield | -198.99% |
Analyst Forecast
The average price target for MEI Pharma is $43.50, which is 987.50% higher than the current price. The consensus rating is "Buy".
Price Target | $43.50 |
Price Target Difference | 987.50% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | -12.18% |
EPS Growth Forecast (5Y) | -27.63% |
Stock Splits
The last stock split was on April 17, 2023. It was a reverse split with a ratio of 1:20.
Last Split Date | Apr 17, 2023 |
Split Type | Reverse |
Split Ratio | 1:20 |
Scores
MEI Pharma has an Altman Z-Score of -2.94 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -2.94 |
Piotroski F-Score | 5 |